As both of them increased the expression level of CRTH2 in DLBCL cells (Fig. 5C), further experiments were performed to elucidate the effects of combination therapy between HDAC inhibitors and CRTH2 inhibitor in DLBCL. This evidence concerns the gene PTGDR2 and diffuse large B-cell lymphoma.